Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL475431 | 1.00 | EPHX1 (0.44) | EPHX1SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18039491 | 0.90 | MME (0.43) | EPHX1SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18039493 | 0.90 | MME (0.43) | EPHX1SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1594425 | 0.86 | PPARG (0.44) | SIGMAR1KMT2AMEN1 | |
| SCHEMBL1594421 | 0.86 | PPARG (0.44) | SIGMAR1KMT2AMEN1 | |
| SCHEMBL475776 | 0.85 | TDP1 (0.36) | EPHX1SIGMAR1KMT2AMEN1L3MBTL1 | |
| SCHEMBL14130060 | 0.85 | TDP1 (0.36) | EPHX1SIGMAR1KMT2AMEN1L3MBTL1 | |
| SCHEMBL475774 | 0.85 | TDP1 (0.36) | EPHX1SIGMAR1KMT2AMEN1L3MBTL1 | |
| SCHEMBL13110181 | 0.85 | BCHE (0.51) | PTGS1L3MBTL1 | |
| SCHEMBL5270401 | 0.85 | BCHE (0.51) | PTGS1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7189864-B2 | Method of preparing intermediates useful in synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-03-13 | — | — | US | claimed |
| US-20050171366-A1 | Method of preparing intermediates useful in synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2005-08-04 | — | — | US | claimed |
| US-20030225285-A1 | Method for preparing intermediates useful in synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. | 2003-12-04 | — | — | US | claimed |
| US-20020161234-A1 | Method of preparing intermediates useful in synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2002-10-31 | — | — | US | claimed |
| EP-0730570-B1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 2000-04-19 | — | — | EP | claimed |
| US-5847201-A | N-protected/N-substituted-beta-amino hydroxy sulfonates | G.D. SEARLE & CO. (US) | 1998-12-08 | — | — | US | claimed |
| US-5583238-A | Method for making intermediates useful in synthesis of retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 1996-12-10 | — | — | US | claimed |
| EP-0730570-A1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-09-11 | — | — | EP | claimed |
| EP-0641333-B1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 1996-08-14 | — | — | EP | claimed |
| WO-1995014653-A1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-06-01 | — | — | WO | claimed |
| EP-0641333-A1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS. | SEARLE & CO (US) | 1995-03-08 | — | — | EP | claimed |
| WO-1993023388-A1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1993-11-25 | — | — | WO | claimed |
| CN-105175364-B | A kind of method for preparing anti-aids drug amprenavir intermediate | 上海应用技术学院 | 2018-05-22 | — | — | CN | disclosed |
| CN-105175364-A | Method for preparing amprenavir midbody serving as anti-AIDS medicine | SHANGHAI INST TECHNOLOGY | 2015-12-23 | — | — | CN | disclosed |
| US-8703947-B2 | Compounds for treatment of Alzheimer's disease | PURDUE RESEARCH FOUNDATION (US) | 2014-04-22 | — | — | US | disclosed |
| US-20130102593-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION | 2013-04-25 | — | — | US | disclosed |
| EP-0657415-A1 | OPTICALLY ACTIVE AMINO ALCOHOL DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | KANEKA CORPORATION (JP) | 1995-06-14 | — | — | EP | disclosed |
| WO-1995006061-A1 | RETROVIRAL PROTEASE INHIBITORS AND COMBINATIONS THEREOF | G.D. SEARLE & CO. (US) | 1995-03-02 | — | — | WO | disclosed |
| WO-1993013066-A1 | CYCLIC AMIDES OF 3-AMINO-2-HYDROXY-CARBOXYLIC ACIDS AS HIV-PROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1993-07-08 | — | — | WO | disclosed |
| US-4990669-A | Optically active α-amino aldehydes, process for the preparation thereof, and the use thereof for the stereoselective preparation of optically active β-amino alcohols | BAYER AKTIENGESELLSCHAFT (DE) | 1991-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161234-A1 | Method of preparing intermediates useful in synthesis of retroviral protease inhibitors | PREP, DNPEP, ANPEP | EPHX1 7/4885SIGMAR1 3015/4885SLC6A2 3936/4885 |
| US-20030225285-A1 | Method for preparing intermediates useful in synthesis of retroviral protease inhibitors | PREP, DNPEP, ANPEP | EPHX1 7/4885SIGMAR1 3006/4885SLC6A2 3836/4885 |
| US-20050171366-A1 | Method of preparing intermediates useful in synthesis of retroviral protease inhibitors | PREP, DNPEP, ANPEP | EPHX1 7/4885SIGMAR1 3015/4885SLC6A2 3936/4885 |
| US-20130102593-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | BACE1, BACE2, APP | EPHX1 1408/4885SIGMAR1 4501/4885SLC6A2 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.